CSF3 and lung cancer: Among HR patients who did not receive G-CSF prophylaxis in cycle 1 (n = 154/299; 51.5%), FN incidence was 7.8% (range: 7.5% [lung cancer] to 8.8% [breast cancer]) during cycle 1 and 16.9% (range: 7.7% [NHL] to 20.6% [breast cancer]) during the course (Fig. 2a–b).